Literature DB >> 11389576

Defining an exacerbation of pulmonary disease in cystic fibrosis.

C Dakin1, R L Henry, P Field, J Morton.   

Abstract

Despite the importance of pulmonary exacerbations in CF in both clinical and research settings, both published evidence and consensus are lacking concerning the criteria used to define an exacerbation. The use of hospitalization as a surrogate measure presupposes uniformity among clinicians in diagnosis and treatment of exacerbations. Our aims were to evaluate consensus among clinicians about the variables considered helpful in diagnosing an exacerbation requiring treatment. A comprehensive list of symptoms, signs, and investigations used to define exacerbations was compiled from published trials. A written self-administered questionnaire included the list in age-appropriate groups to survey opinion about the helpfulness of each item, and the estimated proportion of patients admitted within a month of diagnosis of an exacerbation. This was sent to all clinicians managing CF patients in Australia. There were replies from 59/91 clinicians (65%), 41/60 (68%) from those managing children and 18/31 (58%) from those managing adults. Responses of those managing children and adults differed for 7/32 variables (Mann-Whitney test, P < 0.05). Clinic grouping did not show greater consensus among responses of pediatricians (Kruskal-Wallis test, P = 0.362). Consensus, >74% or <26% of respondents rating a variable helpful/very helpful, was found in only 50% of variables listed. Estimated admission rate within a month of diagnosis was 61% (30-100%) for those managing adults and 48% %5-100%) for pediatricians. A lack of consensus was found among clinicians managing CF about the variables considered in diagnosing an exacerbation. The estimated proportion admitted within a month of diagnosis was very variable. This demonstrated inhomogeneity in approach to diagnosis and management of an exacerbation suggests a significant heterogeneity of clinical care.

Entities:  

Mesh:

Year:  2001        PMID: 11389576     DOI: 10.1002/ppul.1072

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  15 in total

1.  Sleep Patterns in Children with Cystic Fibrosis.

Authors:  Lisa J Meltzer; Suzanne E Beck
Journal:  Child Health Care       Date:  2012

2.  The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

Authors:  Catherine Norrish; Mark Norrish; Uwe Fass; Majid Al-Salmani; Ganji Shiva Lingam; Fiona Clark; Hebal Kallesh
Journal:  Oman Med J       Date:  2015-01

Review 3.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

4.  Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations.

Authors:  Avani C Modi; Crystal S Lim; Kimberly A Driscoll; Carrie Piazza-Waggoner; Alexandra L Quittner; Jamie Wooldridge
Journal:  J Clin Psychol Med Settings       Date:  2010-03

5.  Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis.

Authors:  J A Smith; E C Owen; A M Jones; M E Dodd; A K Webb; A Woodcock
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

6.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Authors:  Scott D Sagel; Valeria Thompson; James F Chmiel; Gregory S Montgomery; Samya Z Nasr; Elizabeth Perkett; Milene T Saavedra; Bonnie Slovis; Margaret M Anthony; Peggy Emmett; Sonya L Heltshe
Journal:  Ann Am Thorac Soc       Date:  2015-05

7.  Increased Plasma YKL-40 Level and Chitotriosidase Activity in Cystic Fibrosis Patients.

Authors:  Dilara Bal Topcu; Gokcen Tugcu; Berrin Er; Sanem Eryilmaz Polat; Mina Hizal; Ebru Elmas Yalcin; Deniz Dogru Ersoz; Lutfi Coplu; Ugur Ozcelik; Nural Kiper; Incilay Lay; Yesim Oztas
Journal:  Inflammation       Date:  2021-10-12       Impact factor: 4.092

8.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

Review 10.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.